The abstract is read at the publisher; the summary is JClub's.
A chemoproteomics-guided inhibitor series covalently targeting NLRP3 Cys463 achieves mid-nanomolar potency and brain-penetrant Kp,uu >0.5, with cryo-EM showing stabilization of an inactive conformation.
- Why it matters: NLRP3 inhibitors are limited in chemical diversity and often lack brain penetration, leaving neuroinflammatory disorders inadequately addressed.
- What they did: The team screened an electrophilic fragment collection using chemoproteomics, prioritized Cys463 binders, solved cryo-EM structures, and tested IL-1β secretion inhibition in a Cys463-dependent manner.
- The result: In humanized mice, a representative compound showed clear Cys463 target engagement and profound suppression of LPS- and ATP-induced IL-1β secretion, supporting in vivo proof-of-concept.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.